LIVIVO - Search results -

Search results

Result 1 - 10 of total 16

Search options

Article ; Online: Genetic investigation of multicentric glioblastoma multiforme: case report.

Schroeder, Brett / Shah, Nameeta / Rostad, Steve / McCullough, Brendan / Aguedan, Brian / Foltz, Greg / Cobbs, Charles

2016 Volume 124, Issue 5, Page(s) 1353–1358

Abstract: The authors report a case of multicentric glioblastoma multiforme (GBM) in which all 4 tumor foci were resected and evaluated using both comparative genomic hybridization array and RNA sequencing. Genetic analysis showed that the tumors shared a common ... ...

Abstract	The authors report a case of multicentric glioblastoma multiforme (GBM) in which all 4 tumor foci were resected and evaluated using both comparative genomic hybridization array and RNA sequencing. Genetic analysis showed that the tumors shared a common origin, although each had its own unique set of genetic aberrations. The authors note that the genetic heterogeneity of multicentric GBM likely contributes to the failures of current treatments. The case underscores the necessity of increased genetic investigation.
MeSH term(s)	Brain Neoplasms/diagnostic imaging ; Brain Neoplasms/genetics ; Brain Neoplasms/pathology ; Brain Neoplasms/surgery ; Cerebral Cortex/diagnostic imaging ; Cerebral Cortex/pathology ; Cerebral Cortex/surgery ; Chemotherapy, Adjuvant ; Combined Modality Therapy ; Comparative Genomic Hybridization ; Craniotomy ; Genetic Heterogeneity ; Glioblastoma/diagnostic imaging ; Glioblastoma/genetics ; Glioblastoma/pathology ; Glioblastoma/surgery ; Hippocampus/diagnostic imaging ; Hippocampus/pathology ; Hippocampus/surgery ; Humans ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Neoplasms, Multiple Primary/diagnostic imaging ; Neoplasms, Multiple Primary/genetics ; Neoplasms, Multiple Primary/pathology ; Neoplasms, Multiple Primary/surgery
Language	English
Publishing date	2016-05
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	3089-2
ISSN	1933-0693 ; 0022-3085
ISSN (online)	1933-0693
ISSN	0022-3085
DOI	10.3171/2015.4.JNS142231
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uk I Zs.135: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number data.

Shah, Nameeta / Lankerovich, Michael / Lee, Hwahyung / Yoon, Jae-Geun / Schroeder, Brett / Foltz, Greg

BMC genomics

2013 Volume 14, Page(s) 818

Abstract: Background: RNA-seq has spurred important gene fusion discoveries in a number of different cancers, including lung, prostate, breast, brain, thyroid and bladder carcinomas. Gene fusion discovery can potentially lead to the development of novel ... ...

Abstract	Background: RNA-seq has spurred important gene fusion discoveries in a number of different cancers, including lung, prostate, breast, brain, thyroid and bladder carcinomas. Gene fusion discovery can potentially lead to the development of novel treatments that target the underlying genetic abnormalities. Results: In this study, we provide comprehensive view of gene fusion landscape in 185 glioblastoma multiforme patients from two independent cohorts. Fusions occur in approximately 30-50% of GBM patient samples. In the Ivy Center cohort of 24 patients, 33% of samples harbored fusions that were validated by qPCR and Sanger sequencing. We were able to identify high-confidence gene fusions from RNA-seq data in 53% of the samples in a TCGA cohort of 161 patients. We identified 13 cases (8%) with fusions retaining a tyrosine kinase domain in the TCGA cohort and one case in the Ivy Center cohort. Ours is the first study to describe recurrent fusions involving non-coding genes. Genomic locations 7p11 and 12q14-15 harbor majority of the fusions. Fusions on 7p11 are formed in focally amplified EGFR locus whereas 12q14-15 fusions are formed by complex genomic rearrangements. All the fusions detected in this study can be further visualized and analyzed using our website: http://ivygap.swedish.org/fusions. Conclusions: Our study highlights the prevalence of gene fusions as one of the major genomic abnormalities in GBM. The majority of the fusions are private fusions, and a minority of these recur with low frequency. A small subset of patients with fusions of receptor tyrosine kinases can benefit from existing FDA approved drugs and drugs available in various clinical trials. Due to the low frequency and rarity of clinically relevant fusions, RNA-seq of GBM patient samples will be a vital tool for the identification of patient-specific fusions that can drive personalized therapy.
MeSH term(s)	DNA Copy Number Variations/genetics ; Gene Expression Profiling ; Glioblastoma/genetics ; Glioblastoma/pathology ; High-Throughput Nucleotide Sequencing ; Humans ; Neoplasm Recurrence, Local/genetics ; Oncogene Proteins, Fusion/classification ; Oncogene Proteins, Fusion/genetics ; Oncogene Proteins, Fusion/isolation & purification ; Transcriptome/genetics
Chemical Substances	Oncogene Proteins, Fusion
Language	English
Publishing date	2013-11-22
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2041499-7
ISSN	1471-2164 ; 1471-2164
ISSN (online)	1471-2164
ISSN	1471-2164
DOI	10.1186/1471-2164-14-818
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Cellular pleomorphism in papillary tumors of the pineal region.

Magalhães, Juliana / Rostad, Steven / Foltz, Greg / Pytel, Peter / Rodriguez, Fausto J

Brain tumor pathology

2012 Volume 30, Issue 2, Page(s) 93–98

Abstract: Papillary tumor of the pineal region (PTPR) is a recently recognized entity. We present the pathologic findings of two cases of PTPR as examples, and discuss the presence of cellular pleomorphism in these tumors. Patient 1 is a 48-year-old man with a ... ...

Abstract	Papillary tumor of the pineal region (PTPR) is a recently recognized entity. We present the pathologic findings of two cases of PTPR as examples, and discuss the presence of cellular pleomorphism in these tumors. Patient 1 is a 48-year-old man with a pineal region mass. The tumor had unique biphasic patterns, papillary/pseudopapillary areas, and increased mitotic activity. Juxtaposed areas had marked pleomorphism, including nuclear enlargement, smudgy chromatin, nuclear pseudoinclusions, and cytoplasmic vacuolation. Mitoses were absent in these areas. Immunohistochemical staining revealed strong S100 expression. CAM 5.2 and CK18 were strongly positive in a patchy fashion. MIB1 labeling indices were high in classic PTPR regions but very low in pleomorphic areas. Patient 2 was a 35-year-old male with a pineal region tumor characterized by papillary architecture and overall cellular monotony, rare mitoses, and pleomorphism as a more isolated finding, with associated nuclear enlargement and crowding. S100 and CAM 5.2 labeling were present, and MIB1 labeling index was very low throughout the tumor. We discuss the pathologic and phenotypic features of PTPR. Variable pleomorphism may be present, reflected in size variation and nuclear hyperchromasia, but was not accompanied by increased proliferative activity in these cases, suggesting a degenerative phenomenon.
MeSH term(s)	Adult ; Biomarkers/metabolism ; Carcinoma, Papillary/metabolism ; Carcinoma, Papillary/pathology ; Humans ; Immunohistochemistry ; Keratins/metabolism ; Male ; Middle Aged ; Pinealoma/metabolism ; Pinealoma/pathology ; S100 Proteins/metabolism
Chemical Substances	Biomarkers ; CAM 5.2 antigen ; S100 Proteins ; Keratins (68238-35-7)
Language	English
Publishing date	2012-05-24
Publishing country	Japan
Document type	Case Reports ; Journal Article
ZDB-ID	1193775-0
ISSN	1861-387X ; 1433-7398 ; 0914-8108
ISSN (online)	1861-387X
ISSN	1433-7398 ; 0914-8108
DOI	10.1007/s10014-012-0103-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 4555: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: A Cell-Surface Membrane Protein Signature for Glioblastoma.

Ghosh, Dhimankrishna / Funk, Cory C / Caballero, Juan / Shah, Nameeta / Rouleau, Katherine / Earls, John C / Soroceanu, Liliana / Foltz, Greg / Cobbs, Charles S / Price, Nathan D / Hood, Leroy

Cell systems

2017 Volume 4, Issue 5, Page(s) 516–529.e7

Abstract: We present a systems strategy that facilitated the development of a molecular signature for glioblastoma (GBM), composed of 33 cell-surface transmembrane proteins. This molecular signature, GBMSig, was developed through the integration of cell-surface ... ...

Abstract	We present a systems strategy that facilitated the development of a molecular signature for glioblastoma (GBM), composed of 33 cell-surface transmembrane proteins. This molecular signature, GBMSig, was developed through the integration of cell-surface proteomics and transcriptomics from patient tumors in the REMBRANDT (n = 228) and TCGA datasets (n = 547) and can separate GBM patients from control individuals with a Matthew's correlation coefficient value of 0.87 in a lock-down test. Functionally, 17/33 GBMSig proteins are associated with transforming growth factor β signaling pathways, including CD47, SLC16A1, HMOX1, and MRC2. Knockdown of these genes impaired GBM invasion, reflecting their role in disease-perturbed changes in GBM. ELISA assays for a subset of GBMSig (CD44, VCAM1, HMOX1, and BIGH3) on 84 plasma specimens from multiple clinical sites revealed a high degree of separation of GBM patients from healthy control individuals (area under the curve is 0.98 in receiver operating characteristic). In addition, a classifier based on these four proteins differentiated the blood of pre- and post-tumor resections, demonstrating potential clinical value as biomarkers.
MeSH term(s)	Biomarkers, Tumor ; Brain Neoplasms/genetics ; Cell Differentiation ; Cell Line, Tumor ; Cell Membrane/metabolism ; Cell Proliferation ; Computational Biology/methods ; Gene Expression Profiling/methods ; Gene Expression Regulation, Neoplastic/genetics ; Glioblastoma/genetics ; Glioblastoma/metabolism ; Humans ; Membrane Proteins/genetics ; Membrane Proteins/metabolism ; Proteomics/methods ; Systems Biology/methods ; Transcriptome/genetics ; Transforming Growth Factor beta/metabolism
Chemical Substances	Biomarkers, Tumor ; Membrane Proteins ; Transforming Growth Factor beta
Language	English
Publishing date	2017-03-29
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ISSN	2405-4712
ISSN	2405-4712
DOI	10.1016/j.cels.2017.03.004
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article ; Online: Targeting stem cells-clinical implications for cancer therapy.

Tu, Lan Chun / Foltz, Greg / Lin, Edward / Hood, Leroy / Tian, Qiang

Current stem cell research & therapy

2009 Volume 4, Issue 2, Page(s) 147–153

Abstract: Cancer stem cells (CSC), also called tumor initiating cells (TIC), are considered to be the origin of replicating malignant tumor cells in a variety of human cancers. Their presence in the tumor may herald malignancy potential, mediate resistance to ... ...

Abstract	Cancer stem cells (CSC), also called tumor initiating cells (TIC), are considered to be the origin of replicating malignant tumor cells in a variety of human cancers. Their presence in the tumor may herald malignancy potential, mediate resistance to conventional chemotherapy or radiotherapy, and confer poor survival outcomes. Thus, CSC may serve as critical cellular targets for treatment. The ability to therapeutically target CSC hinges upon identifying their unique cell surface markers and the underlying survival signaling pathways. While accumulating evidence suggests cell-surface antigens (such as CD44, CD133) as CSC markers for several tumor tissues, emerging clinical needs exist for the identification of new markers to completely separate CSC from normal stem cells. Recent studies have demonstrated the critical role of the tumor suppressor PTEN/PI3 kinase pathway in regulating TIC in leukemia, brain, and intestinal tissues. The successful eradication of tumors by therapies targeting CSC will require an in-depth understanding of the molecular mechanisms governing CSC self renewal, differentiation, and escape from conventional therapy. Here we review recent progress from brain tumor and intestinal stem cell research with a focus on the PTEN-Akt-Wnt pathway, and how the components of CSC pathways may serve as biomarkers for diagnosis, prognosis, and therapeutics.
MeSH term(s)	Animals ; Biomarkers, Tumor/metabolism ; Cell Differentiation/physiology ; Clinical Trials as Topic ; Humans ; Neoplasms/diagnosis ; Neoplasms/pathology ; Neoplasms/therapy ; Neoplastic Stem Cells/cytology ; Neoplastic Stem Cells/physiology ; PTEN Phosphohydrolase/genetics ; PTEN Phosphohydrolase/metabolism ; Prognosis ; Proto-Oncogene Proteins c-akt/genetics ; Proto-Oncogene Proteins c-akt/metabolism ; Signal Transduction/physiology ; Wnt Proteins/genetics ; Wnt Proteins/metabolism
Chemical Substances	Biomarkers, Tumor ; Wnt Proteins ; Proto-Oncogene Proteins c-akt (EC 2.7.11.1) ; PTEN Phosphohydrolase (EC 3.1.3.67) ; PTEN protein, human (EC 3.1.3.67)
Language	English
Publishing date	2009-05-08
Publishing country	United Arab Emirates
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, U.S. Gov't, Non-P.H.S. ; Review
ZDB-ID	2251937-3
ISSN	2212-3946 ; 1574-888X
ISSN (online)	2212-3946
ISSN	1574-888X
DOI	10.2174/157488809788167373
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6399: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: High-throughput chemical screens identify disulfiram as an inhibitor of human glioblastoma stem cells.

Hothi, Parvinder / Martins, Timothy J / Chen, Liping / Deleyrolle, Loic / Yoon, Jae-Geun / Reynolds, Brent / Foltz, Greg

Oncotarget

2012 Volume 3, Issue 10, Page(s) 1124–1136

Abstract: Glioblastoma Multiforme (GBM) continues to have a poor patient prognosis despite optimal standard of care. Glioma stem cells (GSCs) have been implicated as the presumed cause of tumor recurrence and resistance to therapy. With this in mind, we screened a ...

Abstract	Glioblastoma Multiforme (GBM) continues to have a poor patient prognosis despite optimal standard of care. Glioma stem cells (GSCs) have been implicated as the presumed cause of tumor recurrence and resistance to therapy. With this in mind, we screened a diverse chemical library of 2,000 compounds to identify therapeutic agents that inhibit GSC proliferation and therefore have the potential to extend patient survival. High-throughput screens (HTS) identified 78 compounds that repeatedly inhibited cellular proliferation, of which 47 are clinically approved for other indications and 31 are experimental drugs. Several compounds (such as digitoxin, deguelin, patulin and phenethyl caffeate) exhibited high cytotoxicity, with half maximal inhibitory concentrations (IC50) in the low nanomolar range. In particular, the FDA approved drug for the treatment of alcoholism, disulfiram (DSF), was significantly potent across multiple patient samples (IC50 of 31.1 nM). The activity of DSF was potentiated by copper (Cu), which markedly increased GSC death. DSF-Cu inhibited the chymotrypsin-like proteasomal activity in cultured GSCs, consistent with inactivation of the ubiquitin-proteasome pathway and the subsequent induction of tumor cell death. Given that DSF is a relatively non-toxic drug that can penetrate the blood-brain barrier, we suggest that DSF should be tested (as either a monotherapy or as an adjuvant) in pre-clinical models of human GBM. Data also support targeting of the ubiquitin-proteasome pathway as a therapeutic approach in the treatment of GBM.
MeSH term(s)	Alcohol Deterrents/pharmacology ; Animals ; Apoptosis/drug effects ; Blotting, Western ; Brain Neoplasms/drug therapy ; Brain Neoplasms/metabolism ; Brain Neoplasms/pathology ; Cell Proliferation/drug effects ; Disulfiram/pharmacology ; Drug Screening Assays, Antitumor ; Female ; Flow Cytometry ; Glioblastoma/drug therapy ; Glioblastoma/metabolism ; Glioblastoma/pathology ; High-Throughput Screening Assays ; Humans ; Mice ; Mice, Inbred NOD ; Mice, SCID ; Neoplastic Stem Cells/drug effects ; Neoplastic Stem Cells/metabolism ; Small Molecule Libraries/pharmacology ; Tumor Cells, Cultured
Chemical Substances	Alcohol Deterrents ; Small Molecule Libraries ; Disulfiram (TR3MLJ1UAI)
Language	English
Publishing date	2012-11-20
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2560162-3
ISSN	1949-2553 ; 1949-2553
ISSN (online)	1949-2553
ISSN	1949-2553
DOI	10.18632/oncotarget.707
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Late de novo basilar aneurysm after carotid artery injury: case illustration.

Lipson, Adam C / Foltz, Greg / West, G Alexander / Newell, David / Britz, Gavin W

Journal of neurosurgery

2008 Volume 108, Issue 3, Page(s) 607

MeSH term(s)	Adult ; Carotid Artery Injuries/complications ; Fatal Outcome ; Female ; Humans ; Intracranial Aneurysm/diagnostic imaging ; Intracranial Aneurysm/etiology ; Radiography ; Time Factors
Language	English
Publishing date	2008-03
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	3089-2
ISSN	1933-0693 ; 0022-3085
ISSN (online)	1933-0693
ISSN	0022-3085
DOI	10.3171/JNS/2008/108/3/0607
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uk I Zs.135: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Comprehensive analysis of MGMT promoter methylation: correlation with MGMT expression and clinical response in GBM.

Shah, Nameeta / Lin, Biaoyang / Sibenaller, Zita / Ryken, Timothy / Lee, Hwahyung / Yoon, Jae-Geun / Rostad, Steven / Foltz, Greg

PloS one

2011 Volume 6, Issue 1, Page(s) e16146

Abstract: O⁶-methylguanine DNA-methyltransferase (MGMT) promoter methylation has been identified as a potential prognostic marker for glioblastoma patients. The relationship between the exact site of promoter methylation and its effect on gene silencing, and the ... ...

Abstract	O⁶-methylguanine DNA-methyltransferase (MGMT) promoter methylation has been identified as a potential prognostic marker for glioblastoma patients. The relationship between the exact site of promoter methylation and its effect on gene silencing, and the patient's subsequent response to therapy, is still being defined. The aim of this study was to comprehensively characterize cytosine-guanine (CpG) dinucleotide methylation across the entire MGMT promoter and to correlate individual CpG site methylation patterns to mRNA expression, protein expression, and progression-free survival. To best identify the specific MGMT promoter region most predictive of gene silencing and response to therapy, we determined the methylation status of all 97 CpG sites in the MGMT promoter in tumor samples from 70 GBM patients using quantitative bisulfite sequencing. We next identified the CpG site specific and regional methylation patterns most predictive of gene silencing and improved progression-free survival. Using this data, we propose a new classification scheme utilizing methylation data from across the entire promoter and show that an analysis based on this approach, which we call 3R classification, is predictive of progression-free survival (HR = 5.23, 95% CI [2.089-13.097], p<0.0001). To adapt this approach to the clinical setting, we used a methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) test based on the 3R classification and show that this test is both feasible in the clinical setting and predictive of progression free survival (HR = 3.076, 95% CI [1.301-7.27], p = 0.007). We discuss the potential advantages of a test based on this promoter-wide analysis and compare it to the commonly used methylation-specific PCR test. Further prospective validation of these two methods in a large independent patient cohort will be needed to confirm the added value of promoter wide analysis of MGMT methylation in the clinical setting.
MeSH term(s)	Base Sequence ; CpG Islands ; DNA Methylation/genetics ; DNA Modification Methylases/biosynthesis ; DNA Modification Methylases/genetics ; DNA Repair Enzymes/biosynthesis ; DNA Repair Enzymes/genetics ; Disease-Free Survival ; Gene Silencing ; Glioblastoma/enzymology ; Glioblastoma/genetics ; Glioblastoma/mortality ; Glioblastoma/pathology ; Humans ; Prognosis ; Promoter Regions, Genetic/genetics ; Treatment Outcome ; Tumor Suppressor Proteins/biosynthesis ; Tumor Suppressor Proteins/genetics
Chemical Substances	Tumor Suppressor Proteins ; DNA Modification Methylases (EC 2.1.1.-) ; MGMT protein, human (EC 2.1.1.63) ; DNA Repair Enzymes (EC 6.5.1.-)
Language	English
Publishing date	2011-01-07
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ISSN	1932-6203
ISSN (online)	1932-6203
DOI	10.1371/journal.pone.0016146
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Epigenetic regulation of wnt pathway antagonists in human glioblastoma multiforme.

Foltz, Greg / Yoon, Jae-Geun / Lee, Hwahyung / Ma, Li / Tian, Qiang / Hood, Leroy / Madan, Anup

Genes & cancer

2011 Volume 1, Issue 1, Page(s) 81–90

Abstract: Epigenetic inactivation of tumor suppressor genes is common in human cancer. Using a large-scale whole-genome approach in an earlier study, the authors identified epigenetically silenced genes with potential tumor suppressor function in glioblastoma (GBM) ...

Abstract	Epigenetic inactivation of tumor suppressor genes is common in human cancer. Using a large-scale whole-genome approach in an earlier study, the authors identified epigenetically silenced genes with potential tumor suppressor function in glioblastoma (GBM). Three genes identified in this analysis-DKK1, SFRP1, and WIF1-are potent inhibitors of the Wnt signal transduction pathway. Here, the authors confirm decreased expression of these genes in GBM tumor tissue samples relative to nontumor brain tissue samples using real-time PCR. They then show that expression of all 3 genes is restored in T98 GBM cells by treatment with the histone deacetylase inhibitor Trichostatin A (TSA), but only DKK1 expression is restored by treatment with the demethylating agent 5-azacytidine. Bisulfite sequencing did not reveal significant methylation in the promoter region of DKK1, whereas histone acetylation and chromatin accessibility increased significantly for all 3 genes after TSA treatment. Ectopic expression of DKK1 significantly reduces colony formation and increases chemotherapy-induced apoptosis in T98 cells. Ectopic expression of the canonical Wnt pathway inhibitors WIF1 and SFRP1 shows a relative lack of response. Chronic Wnt3a stimulation only partially reverses growth suppression after DKK1 reexpression, whereas a specific inhibitor of the JNK pathway significantly reverses the effect of DKK1 reexpression on colony formation and apoptosis in T98 cells. These results support a potential growth-suppressive function for epigenetically silenced DKK1 in GBM and suggest that DKK1 restoration could modulate Wnt signaling through both canonical and noncanonical pathways.
Language	English
Publishing date	2011-07-14
Publishing country	United States
Document type	Journal Article
ZDB-ID	2538519-7
ISSN	1947-6027 ; 1947-6019
ISSN (online)	1947-6027
ISSN	1947-6019
DOI	10.1177/1947601909356103
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Systems biology and cancer stem cells.

Price, Nathan D / Foltz, Greg / Madan, Anup / Hood, Leroy / Tian, Qiang

Journal of cellular and molecular medicine

2007 Volume 12, Issue 1, Page(s) 97–110

Abstract: The identification, purification, and characterization of cancer stem cells holds tremendous promise for improving the treatment of cancer. Mounting evidence is demonstrating that only certain tumor cells (i.e. the cancer stem cells) can give rise to ... ...

Abstract	The identification, purification, and characterization of cancer stem cells holds tremendous promise for improving the treatment of cancer. Mounting evidence is demonstrating that only certain tumor cells (i.e. the cancer stem cells) can give rise to tumors when injected and that these purified cell populations generate heterogeneous tumors. While the cell of origin is still not determined definitively, specific molecular markers for populations containing these cancer stem cells have been found for leukemia, brain cancer, and breast cancer, among others. Systems approaches, particularly molecular profiling, have proven to be of great utility for cancer diagnosis and characterization. These approaches also hold significant promise for identifying distinctive properties of the cancer stem cells, and progress is already being made.
MeSH term(s)	Animals ; Humans ; Neoplasms/pathology ; Neoplastic Stem Cells/pathology ; Systems Biology
Language	English
Publishing date	2007-11-20
Publishing country	England
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	2074559-X
ISSN	1582-4934 ; 1582-1838 ; 1582-4934
ISSN (online)	1582-4934
ISSN	1582-1838 ; 1582-4934
DOI	10.1111/j.1582-4934.2007.00151.x
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5752: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito